New York Fashion Week begins with a history lesson. And it’s a surprising amount of fun.
NYS Entity Status
NYS Filing Date
JUNE 12, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - DONNA DAVID & CO LTD.
Around the Web
- Fashion Review: Tom Ford Exhumes the 1990s and It’s Almost Fabulous
By VANESSA FRIEDMAN - Thursday Sep 7, 2017
- David Geffen Criticizes ‘Shameful’ Lack of Support for Concert Hall
By ROBIN POGREBIN and MICHAEL COOPER - Wednesday Oct 4, 2017
Mr. Geffen lamented the downsizing of the $500 million David Geffen Hall project at Lincoln Center. “New York should have the best of everything,” he said.
- Todd Frazier making case for NY return — but not with Yankees?
By Joel Sherman - Tuesday Oct 17, 2017
Todd Frazier was the third piece in a three-player package the Yankees received in July, present as much because the White Sox wanted to unload the rest of his salary as the Yankees hungered for his inclusion. Tommy Kahnle was priority one for the Yankees, David Robertson the second key, both made more attractive because...
- Detained Samsung scion’s wealth just topped $2 billion
By Reuters - Friday Oct 13, 2017
SEOUL – Jay Y. Lee, the billionaire heir to South Korea’s Samsung Group, should find some comfort that its crown jewel Samsung Electronics Co Ltd has reported record profit every quarter since he was jailed in February, making him even richer. Detained over charges that he bribed former president Park Geun-hye, Lee has since missed...
- Behind an $18 Billion Donation to a New York Charity, a Shadowy Chinese Conglomerate
By MICHAEL FORSYTHE and ALEXANDRA STEVENSON - Wednesday Jul 26, 2017
A Chinese man has transferred more than 29 percent of HNA Group of China to a private foundation, adding to the questions about the firm’s structure and political connections.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]